Patients must have resolved any serious infectious complications related to therapy Active infectious disease considered by the Investigator to be incompatible with the protocol. Patients with an active infectious disease requiring deferral of conditioning; as recommended by an infectious disease specialist DONOR: With active infectious hepatitis Baseline chest x-ray with no evidence of active infectious disease or pneumonitis Patients with evidence of active, non-infectious pneumonia New or progressive pulmonary infiltrates concerning for new or uncontrolled infectious process Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to weeks ( days) before receiving nivolumab Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to weeks ( days) before receiving nivolumab Patients must not have any active infectious process. If recent mold infection (e.g. aspergillus) must have minimum of days of therapy and responsive disease and be cleared by infectious disease Patients who have active infectious hepatitis Any active infection or infectious illness unless fully recovered prior to dosing. Presence of leukemic or infectious pulmonary parenchymal disease PART : Active or recent (prior month) invasive fungal infection without infectious disease (ID) consult and approval No clinical evidence of uncontrolled active infectious process (ELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED AUTOLOGOUS T CELLS): No clinical evidence of uncontrolled active infectious process No clinical evidence of uncontrolled active infectious process Infectious diseases: no clinical evidence of uncontrolled active infectious process Infectious diseases criteria: no clinical evidence of uncontrolled active infectious process DONOR: Infectious disease testing will be done per Hemacare policy and AAAB guidelines DONOR: Active infectious hepatitis Patients with any infectious process that, in the opinion of the investigator, could worsen or its outcome be affected as a result of the investigational therapy If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease to proceed Active or recent (prior month) invasive fungal infection without infectious diseases (ID) consult and approval If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease Active or recent (prior month) invasive fungal infection without infectious disease (ID) consult and approval If recent mold infection e.g. Aspergillus - must have minimum of days of appropriate treatment before bone marrow transplant (BMT) and infection controlled and be cleared by Infectious Disease Presence of active infectious oral disease excluding oral candidiasis Presence of active infectious disease excluding oral candidiasis Patients must not have any active infectious process. Patients who test positive for infectious hepatitis types A, B, or C within days of registration are NOT eligible for participation Infectious disease testing will be done per Hemacare policy and AAAB guidelines Patients must have resolved any serious infectious complications related to consolidation cycle If recent mold infection (e.g. aspergillus) must have minimum of days of therapy and responsive disease and be cleared by infectious disease With active infectious disease requiring deferral of conditioning, as recommended by an infectious disease specialist DONOR: Individuals with active infectious hepatitis Due to the possible effect of treatment with ipilimumab on the immunologic response to infectious disease vaccines, patients must not have had any infectious disease vaccination (e.g, standard influenza, HN influenza, pneumococcal, meningococcal, tetanus toxoid) within weeks prior to randomization Has an active infectious process Current active infectious disease Have clinical evidence of concomitant infectious conditions. All HIV+ patients will be under the care of an infectious diseases specialist; if a relationship with an infectious diseases specialist is not established, infectious disease specialist will be consulted; records of all viral counts and peripheral T-cell counts must be sent to the study coordinator in order to follow these values over the course of treatment No clinical evidence of uncontrolled active infectious process Active or recent (prior month) invasive fungal infection without infectious disease (ID) consult and approval If recent mold infection (e.g. Aspergillus) must have minimum of days of therapy and responsive disease and be cleared by infectious disease Infectious process, which, in the opinion of the investigator, could worsen or its outcome be affected, as a result of the investigational therapy Active infectious disease concerns Laboratory or clinical evidence of active infectious hepatitis Patients with an active infectious disease Has an active infectious process Active uncontrolled infection or severe infectious disease Active uncontrolled infection or severe infectious disease Active uncontrolled infectious diseases requiring treatment Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B. Any serious concomitant illness or infectious disease requiring treatment, or infectious disease not requiring treatment, but with significant risks for myelosuppressive complications associated with chemotherapy. Any infectious disease requiring treatment at the time of enrolment or within the previous weeks. Serious active infectious disease Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis Active infectious disease considered by the Investigator to be incompatible with the protocol. Active infectious disease excluding oral candidiasis Known positive for infectious hepatitis type C or active infectious hepatitis type B Has active infectious disease undergoing systemic treatment excluding oral candidiasis Active infectious disease excluding oral candidiasis Patients with ongoing febrile illness or documented infectious disease Active, uncontrolled infection or severe infectious disease. Current active infectious disease.